​

Funding Round

Series B - Capstan Therapeutics

Series B - Capstan Therapeutics

Investment Firm

Overview

Capstan Therapeutics is advancing cell engineering to develop therapeutics for a broad range of diseases.

Announced Date

Mar 20, 2024

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

RA Capital Management

RA Capital Management

RA Capital Management is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

13

Investor Name
Participant InvestorOrbiMed
Participant InvestorSofinnova Investments
Participant InvestorNovartis Venture Fund
Participant InvestorBristol-Myers Squibb
Participant InvestorPolaris Partners

Round Details and Background

Capstan Therapeutics raised $175000000 on 2024-03-20 in Series B

Capstan Therapeutics is advancing cell engineering to develop therapeutics for a broad range of diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Sep 14, 2022
Series A - Capstan Therapeutics
10-102.0M
Nov 01, 2021
Seed Round - Capstan Therapeutics
4-63.0M
Mar 20, 2024
Series B - Capstan Therapeutics
15-175.0M

Recent Activity

There is no recent news or activity for this profile.